Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

The human T cell response to melanoma antigens.

Romero P, Cerottini JC, Speiser DE.

Adv Immunol. 2006;92:187-224. Review.

PMID:
17145305
2.

T cell-mediated immune responses in melanoma: implications for immunotherapy.

Wang RF, Zeng G, Johnston SF, Voo K, Ying H.

Crit Rev Oncol Hematol. 2002 Jul;43(1):1-11. Review.

PMID:
12098604
3.

The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.

Anichini A, Vegetti C, Mortarini R.

Cancer Immunol Immunother. 2004 Oct;53(10):855-64. Review.

PMID:
15175905
4.

Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination.

Romero P, Cerottini JC, Speiser DE.

Cancer Immunol Immunother. 2004 Mar;53(3):249-55. Review.

PMID:
14704832
5.

Melanoma cancer vaccines and anti-tumor T cell responses.

Vujanovic L, Butterfield LH.

J Cell Biochem. 2007 Oct 1;102(2):301-10. Review.

PMID:
17647270
6.
7.

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

Maccalli C, Scaramuzza S, Parmiani G.

Cancer Immunol Immunother. 2009 May;58(5):801-8. doi: 10.1007/s00262-008-0635-x. Review.

PMID:
19089424
8.

T-cell recognition of melanoma-associated antigens.

Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G.

J Cell Physiol. 2000 Mar;182(3):323-31. Review.

PMID:
10653598
9.

Natural T cell immunity against cancer.

Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U.

Clin Cancer Res. 2003 Oct 1;9(12):4296-303. Review.

10.

Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.

Gajewski TF.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2326s-2330s. Review.

11.

T cell responses to human malignant tumours.

Knuth A, Wölfel T, Meyer zum Büschenfelde KH.

Cancer Surv. 1992;13:39-52. Review.

PMID:
1423325
12.

Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.

Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN.

Oncogene. 2003 May 19;22(20):3180-7. Review.

PMID:
12789294
13.

[General principles and first clinical trials of therapeutic vaccines against cancer].

Baurain JF, Van der Bruggen P, Van den Eynde BJ, Coulie PG, Van Baren N.

Bull Cancer. 2008 Mar;95(3):327-35. doi: 10.1684/bdc.2008.0588. Review. French.

14.

Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation.

Spagnoli GC, Adamina M, Bolli M, Weber WP, Zajac P, Marti W, Oertli D, Heberer M, Harder F.

World J Surg. 2005 Jun;29(6):692-9. Review.

PMID:
15883665
15.

Immune monitoring of T-cell responses in cancer vaccine development.

Keilholz U, Martus P, Scheibenbogen C.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2346s-2352s. Review.

16.

Antigen recognition and T-cell biology.

Nishimura MI, Roszkowski JJ, Moore TV, Brasic N, McKee MD, Clay TM.

Cancer Treat Res. 2005;123:37-59. Review.

PMID:
16211865
17.

Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.

Gajewski TF.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61. Review.

18.

Human tumor antigens recognized by T-cells.

Kawakami Y, Rosenberg SA.

Immunol Res. 1997;16(4):313-39. Review.

PMID:
9439758
19.

Active-specific immunization against melanoma: is the problem at the receiving end?

Monsurrò V, Wang E, Panelli MC, Nagorsen D, Jin P, Katia Z, Smith K, Ngalame Y, Even J, Marincola FM.

Semin Cancer Biol. 2003 Dec;13(6):473-80. Review.

PMID:
15001166
20.

Melanoma vaccines.

Chapman PB.

Semin Oncol. 2007 Dec;34(6):516-23. Review.

PMID:
18083375
Items per page

Supplemental Content

Support Center